Buradasınız

Anasayfa » Content

HEMODİYALİZ HASTALARINDA FONKSİYONEL DEMİR EKSİKLİĞİNİN TEDAVİSİNDE İNTRAVENÖZ ASKORBİK ASİT'İN KULLANIMI

INTRAVENOUS ASCORBIC ACID IN HEMODIALYSIS PATIENTS WITH IRON DEFICIENCY

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2003

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Background: Functional iron deficiency may develop and cause recombinant human erytropoietin (rHuEpo) resistance in hemodialysis patients (HD) with iron overload. The aim of this study was to show the effects of intravenous ascorbic acid on functional iron deficiency in HD. Patients and Methods: Thirty-four HD patients with serum ferritin>500pg/l, transferin saturation (TS) <% 20 and hemoglobin (Hb) <10 g/dl were randomly divided into two groups. In group I patients (n-16) did not receive any adjuvant therapy. In group II patient (n=18) intravenous ascorbic acid 500 mg was administered three times a week for 12 weeks. Results: All patient completed the study. The mean values ofHb, Hct, TS, and ferritin remained unchanged in group I after 12 weeks. Mean values ofHb, Hct, and TS significantly increased (basaline vs 12 weeks, Hb 9.2+0.3 g/dl vs 10.8+O.3 g/dl, Hct 27.6+0.9% vs 32+0.6%, TS 17.3+1.2% vs 29.9±1.3% respectively p<0.001) in group II after 12 weeks; ferritin fell significantly from 866± 245 i/l vs 646± 219 1 (p<0.001). Conclusion: In this study, 300 mg intravenous ascorbic acid therapy on functional iron deficiency in HD patients was effectively.
Bookmark/Search this post with
Abstract (Original Language): 
Giriş ve Amaç: Hemodiyaliz (HD) hastalarında aşırı demir birikimine bağlı olarak recombinant human erytropoietin (rHuEpo)'e direnç gelişmesi nedeni ile fonksiyonel demir eksikliği gelişebilir. Bu çalışmada fonksiyonel demir eksikliği olan HD hastalarında intravenöz askorbik asitin etkisini göstermeyi amaçladık. Materyal ve Metod: Serum ferritin>500 ıg/l, transferrin satürasyonu (TS) <%20 ve hemoglobin (Hb) <10 g/dl olan 34 HD hastası rastgele iki gruba ayrıldı. 1. gruptaki hastalar (n=16) hiçbir tedavi almadı. II. gruptaki hastalara (n=18) haftada 3 gün 500 mg/gün intravenöz askorbik asit 72 hafta uygulandı. Bulgular: Bütün hastalar çalışmayı tamamladılar. Ortalama Hb, Hct, TS, ve ferritin seviyeleri I. grupta 12 hafta sonunda değişmeden kaldı (p>0.05). Ortalama Hb, Hct, ve TS seviyeleri II. grupta 72 hafta sonunda önemli derecede artn.(Bazal ve 12 hafta sonraki değerleri sırasıyla Hb 9.2±0.3 g/dl - 10.8±0.3 g/dl, Hct% 27.6+0.9 - %32±0.6, TS %17.3±1.2 - %29.9±1.3 olarak bulundu p<0.001). Serum ferritin düzeyleri ise 12 hafta sonra (866+ 245 //// -646± 219 /<//) önemli derecede azaldı p<0.001). Sonuç: Bu çalışmada fonksiyonel demir eksikliği olan HD hastalarında 300 mg intravenöz askorbik asit etkili bulundu.
FULL TEXT (PDF): 
PDF icon pdf_tndt_456.pdf
  • 4
221-224
  • Turkish

REFERENCES

References: 

1. Tarng D, Huang T. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephnol Dial Transplant 1998; 13: 2867-2872.
2. Giancaspro V, Nuzziello M, Pallotta G et al. Intravenous ascorbic acid in hemodialysis patients with iron deficiency : a clinical trial. J Nephrol 2000; 13: 444-449.
3. Scigalla P, Messigner D, Wieczorek L. Reasons for differences in dose requirements of recombinant human erythropoietin in haemodialysis patients. Contrib
Nephrol 1990; 82: 55-64.
4. McDougall 1C, Hutton RD, Cavill I et al. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. Br Med J 1989;
29: 157-158.
5. Bridges KR, Hoffman KE. The effect of ascorbic acid on the intracellular metabolism of iron and ferritin. J
Biol Chem 1986;261:14273-14277.
6. Gastaldello K, Vereerstraeten A, Nzame -Nze T et al. Resistance to erythropoietin in iron-overloaded hemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant 1995; 10(suppl
6): 44-47.
7. El-Reshaid K, Johny KV, Hakim A, et al. .
Erythropoietin treatment in hemodialysis patients with
iron overload. Acta Haematol 1994;91:130-135.
8. Tarng D, Huang T, Wei Y. Erythropoietin and iron: the role of ascorbic acid. Nephrol Dial Ttansplant 2001; 16: 35-39.
9. Lipschitz DA, Bothwell TH, Seftel HC et al. The role of
ascorbic acid in the metabolism of storage iron. Br J
Haematol 1971; 20: 155-163.
10. Goldberg A. The enzymic formation of haem by the incorporation of iron into protoporphyrin: importance of ascorbic acid, ergothioneine and glutathione. Br J
Haematol 1959; 5: 150-157.
11. Pru C, Eaton J, Kjellstrand C. Vitamin C intoxication and hyperoxalemia in chronic hemodialysis patients.
Nephron 1985; 39: 112-116.
12. Alkhunaizi AM, Chan L. Secondary oxalosis: A cause of delayed recovery of renal function in the setting of acute renal failure. J Am Soc Nephrol 1996; 7: 2320¬2326.
13. Costello JF, Sadovnic MJ, Cottington EM. Plasma oxalate levels in hemodialysis patients despite increased
oxalate removal. J Am Soc Nephrol 1991; 1: 1289-1298.
14. Tarng D, Wei Y, Huang T et al. Intrravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with
hyperferritinemia. Kidney Int 1999; 55: 2477-2486.
15. Sezer S, Ozdemir FN, Yakupoğlu U ve ark. Intrravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis
patients. Artif Organs 2002; 26: 366-370.

Thank you for copying data from http://www.arastirmax.com